Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

导出原文传递

翻译打印收藏纠错

作者： Paez, David ^[1] ; Tobena, Maria ^[2] ; Fernandez-Plana, Julen ^[3] ; Sebio, Ana ^[4] ; Virgili, Anna C. ; Cirera, Lluis ; Barnadas, Agusti ; Riera, Pau ; Sullivan, Ivana ; Salazar, Juliana

作者单位： Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain ^[1] CIBERER, U705, Barcelona, Spain ^[2] Hosp Santa Creu & Sant Pau, Genet Dept, Barcelona, Spain ^[3] Hosp Univ Mutua Terrassa, Med Oncol Dept, Terrassa, Spain ^[4]

发布时间 2019-06-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The British journal of cancer

2019年120卷2期

190-195页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

检索历史清除